WARRINGTON, Pa., March 16, 2016 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will report fourth quarter 2015 financial results and provide business updates on Thursday, March 24, 2016 before the open of the U.S. financial markets.
The Company will also host a live teleconference and webcast, including a slide presentation, at 8:00 a.m. EDT on the same day to discuss the 2015 fourth quarter financial results along with providing other business updates. The live webcast and archive of the conference call can be accessed at http://discoverylabs.investorroom.com/events.
For "listen-only" participants and those who wish to take part in the question and answer portion of the call, dial (888) 346-0767 (domestic) or (412) 902-4251 (international). After placing the call, request to be joined into the Discovery Labs conference call. A replay of the conference call will be accessible one hour after completion through March 31, 2016 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing conference ID number 10082877.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lung and are essential for normal respiratory function and survival. If surfactant deficiency or degradation occurs, the air sacs in the lungs can collapse, resulting in severe respiratory diseases and disorders. Discovery Labs' technology platform includes a novel synthetic peptide-containing (KL4) surfactant, that is structurally similar to pulmonary surfactant, and proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of aerosolized surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.
For more information, please visit the Company's website at www.Discoverylabs.com.
SOURCE Discovery Laboratories, Inc.